The role of Id2 in gut innate lymphoid cells
The role of Id2 in gut innate lymphoid cells
批准号:
9278154
负责人:
YANG-XIN FU
金额:
$35.24万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-10 至 2018-05-31
关键词:
AcuteAddressBiological AssayCitrobacter rodentiumColitisDataDevelopmentE proteinExhibitsHomeostasisHost DefenseID2 geneIL7R geneImmune responseImmunityInfectionInfection preventionLymphoidLymphoid CellMaintenanceMediatingModelingMolecularMorbidity - disease rateMusPathogenicityPathway interactionsPlayProductionReagentRegulationReportingRoleSTAT3 geneSignal TransductionStat5 proteinSymbiosisTestingTreatment EfficacyTumor Necrosis Factor-Betacombatexperienceexperimental studyglobal healthinsightinterleukin-22mortalitypathogenprogenitorprotein Epublic health relevanceresponsetranscription factor
中文摘要
描述(由申请人提供):急性粘膜感染仍然是一个首要的全球健康问题。ROR γ t+第3组先天淋巴样细胞(ILC3)中的ROR γ t和IL23/STAT3信号传导对于IL-22的产生至关重要,而IL-22是预防啮齿类柠檬酸杆菌结肠炎所需的。我们最近发现,ILC3的光毒素(LT)也可以控制IL-22的产生。IL-7R信号传导是维持ILC3所必需的。转录因子Id2是ILC祖细胞发育所需的,因为Id2-/-小鼠缺乏所有ILC谱系;然而,Id2在ILC3发育后仍然高度表达,并且仍然不清楚Id2是否调节分化的ROR γ t + ILC3的功能,以及如果是,这是如何执行的。为了阐明Id2在ILC3的稳态和/或功能中的作用,我们仅在其ROR γ t + ILC3中产生Id2缺陷的小鼠(ROR γ t-Id2-/-小鼠),并观察到它们具有减少的ILC3以及减少的IL-7R、IL-23R、LT和IL-22表达,并且变得对C.啮齿类感染令人惊讶的是,将ROR γ t-Id2-/-小鼠与WT小鼠共饲养降低了ROR γ t-Id2-/-小鼠的死亡率和发病率。我们假设分化的ROR γ t + ILC3 s中的Id2表达是ILC3 s的稳态和功能所必需的,ILC3 s可以控制肠道植物群对抗肠道中的病原体定殖。在目标1中,我们将确定Id2如何调节各种ILC3亚群的发育。我们将测试是否需要Id2来控制IL-7R通路以及如何调节。我们还将研究Id2是否通过IL-7R信号传导控制ILC3的存活或增殖能力。最后,我们将确定Id2和E蛋白的相互作用如何控制IL-7R/STAT5通路。在目标2中,我们将定义Id2如何控制主机对C的防御。啮齿类感染我们将测试ILC3中Id2的表达是否促进IL-22的产生,这是针对C.啮齿类感染我们将测试Id2是否通过IL-23R途径内在地调节IL-22的产生以保护宿主免受感染。我们还将确定Id2如何控制ILC3s上的LT表达,从而外源性调节IL-22的产生以对抗C。啮齿类感染在目标3中,我们将确定Id2是否控制C。通过调节和维持肠道植物群与C.啮齿动物。如果是这样,我们将测试Id2依赖性反应如何调节保护性肠道植物群对抗C。啮齿动物。我们将进一步确定选择是否由ILC3衍生的IL-22介导。最后,我们将确定Id2依赖的肠道植物群如何控制C。啮齿类感染研究ROR γ t + ILC3中的Id2将为ILC3的发育和功能提供新的见解,这有助于肠道植物群的稳态,从而保护肠道免受粘膜感染。
英文摘要
DESCRIPTION (provided by applicant): Acute mucosal infections remain a foremost global health problem. RORγt and IL23/STAT3 signaling in RORγt+ group-3 innate lymphoid cells (ILC3s) are critical for IL-22 production required for protection against Citrobacter rodentium colitis. We recently showed that lymphotoxin (LT) from ILC3s could also control IL-22 production. IL-7R signaling is required for maintaining ILC3s. The transcription factor Id2 is required for ILC progenitor development, since Id2-/- mice lack all ILC lineages; however, Id2 is still highly expressed after ILC3 development, and it remains unclear whether or not Id2 regulates the function of differentiated RORγt+ ILC3s and, if so, how this is executed. To address the role of Id2 in the homeostasis and/or function of ILC3s, we generated mice deficient in Id2 only in their RORγt+ ILC3s (RORγt-Id2-/- mice) and observed that they have reduced ILC3s with diminished IL-7R, IL-23R, LT and IL-22 expression and became highly susceptible to C. rodentium infection. Surprisingly, cohousing RORγt-Id2-/- mice with WT mice reduced mortality and morbidity of RORγt-Id2-/- mice. We hypothesize that Id2 expression in differentiated RORγt+ ILC3s is required for the homeostasis and function of ILC3s, which can control commensal flora against pathogen colonization in the gut. In Aim 1, we will determine how Id2 regulates the development of various ILC3 subsets. We will test whether or not Id2 is required to control the IL-7R pathway and how this is regulated. We will also study whether or not Id2 controls the survival or proliferative capacity of ILC3s through IL-7R signaling. Finally, we will determine how interaction of Id2 and E protein controls the IL-7R/STAT5 pathway. In Aim 2, we will define how Id2 controls host defense against C. rodentium infection. We will test whether or not Id2 expression in ILC3s promotes IL-22 production, which is required for protection against C. rodentium infection. We will test whether Id2 intrinsically regulates IL-22 production through the IL-23R pathway to protect the host against an infection. We will also determine how Id2 controls LT expression on ILC3s for extrinsic regulation of IL-22 production against C. rodentium infection. In Aim 3, we will determine whether Id2 controls C. rodentium infection through regulating and maintaining a gut flora capable of competing with C. rodentium. If so, we will test how an Id2- dependent response regulates the protective gut flora against C. rodentium. We will further determine whether the selection is mediated by ILC3-derived IL-22. Finally, we will determine how an Id2- dependent gut flora controls C. rodentium infection. Studying Id2 in RORγt+ ILC3s will provide new insights into ILC3 development and function, which contribute to the homeostasis of gut flora that protects against a mucosal infection in the gut.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI:
10.4049/jimmunol.1600867
发表时间:
2017-01-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Wroblewska JA, Zhang Y, Tang H, Guo X, Nagler C, Fu YX]
通讯作者:
Fu YX
The tragic fate of group 3 innate lymphoid cells during HIV-1 infection.
HIV-1 感染期间第 3 组先天淋巴细胞的悲惨命运。
DOI:
10.1172/jci83823
发表时间:
2015
期刊:
The Journal of clinical investigation
影响因子:
--
作者:
[Guo,Xiaohuan, Fu,Yang-Xin]
通讯作者:
Fu,Yang-Xin
The role of Id2 in gut innate lymphoid cells
-
批准号:8757488
-
项目类别:
-
资助金额:$33.88万
-
财政年份:2014
-
负责人:YANG-XIN FU
-
依托单位:
The role of Id2 in gut innate lymphoid cells
-
批准号:8884597
-
项目类别:
-
资助金额:$33.88万
-
财政年份:2014
-
负责人:YANG-XIN FU
-
依托单位:
The role of Id2 in gut innate lymphoid cells
-
批准号:9064124
-
项目类别:
-
资助金额:$35.21万
-
财政年份:2014
-
负责人:YANG-XIN FU
-
依托单位:
Novel therapeutic approaches to treating chronic hepatitis B virus infection
-
批准号:9054115
-
项目类别:
-
资助金额:$48.69万
-
财政年份:2013
-
负责人:YANG-XIN FU
-
依托单位:
Novel therapeutic approaches to treating chronic hepatitis B virus infection
-
批准号:8577616
-
项目类别:
-
资助金额:$49.99万
-
财政年份:2013
-
负责人:YANG-XIN FU
-
依托单位:
Novel therapeutic approaches to treating chronic hepatitis B virus infection
-
批准号:8701289
-
项目类别:
-
资助金额:$48.69万
-
财政年份:2013
-
负责人:YANG-XIN FU
-
依托单位:
Novel therapeutic approaches to treating chronic hepatitis B virus infection
-
批准号:8725851
-
项目类别:
-
资助金额:$6.51万
-
财政年份:2013
-
负责人:YANG-XIN FU
-
依托单位:
Novel therapeutic approaches to treating chronic hepatitis B virus infection
-
批准号:8840940
-
项目类别:
-
资助金额:$55.2万
-
财政年份:2013
-
负责人:YANG-XIN FU
-
依托单位:
TNF family members for lymph angiogenesis and lymph node hypertrophy
-
批准号:8616723
-
项目类别:
-
资助金额:$30.46万
-
财政年份:2010
-
负责人:YANG-XIN FU
-
依托单位:
TNF family members for lymph angiogenesis and lymph node hypertrophy
-
批准号:8448978
-
项目类别:
-
资助金额:$29.52万
-
财政年份:2010
-
负责人:YANG-XIN FU
-
依托单位:
Synergy of radiation and immunotherapy: new approaches
-
批准号:8408791
-
项目类别:
-
资助金额:$33.2万
-
财政年份:2010
-
负责人:YANG-XIN FU
-
依托单位:
TNF family members for lymph angiogenesis and lymph node hypertrophy
-
批准号:8232145
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2010
-
负责人:YANG-XIN FU
-
依托单位:
Synergy of radiation and immunotherapy: new approaches
-
批准号:8197934
-
项目类别:
-
资助金额:$35.32万
-
财政年份:2010
-
负责人:YANG-XIN FU
-
依托单位:
Synergy of radiation and immunotherapy: new approaches
-
批准号:7985977
-
项目类别:
-
资助金额:$16.19万
-
财政年份:2010
-
负责人:YANG-XIN FU
-
依托单位:
TNF family members for lymph angiogenesis and lymph node hypertrophy
-
批准号:8068874
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2010
-
负责人:YANG-XIN FU
-
依托单位:
TNF family members for lymph angiogenesis and lymph node hypertrophy
-
批准号:7932702
-
项目类别:
-
资助金额:$32.37万
-
财政年份:2010
-
负责人:YANG-XIN FU
-
依托单位:
The Role of Negative Signal in Early Infection
-
批准号:7976664
-
项目类别:
-
资助金额:$19.5万
-
财政年份:2010
-
负责人:YANG-XIN FU
-
依托单位:
Synergy of radiation and immunotherapy: new approaches
-
批准号:8103271
-
项目类别:
-
资助金额:$35.32万
-
财政年份:2010
-
负责人:YANG-XIN FU
-
依托单位:
The Role of Negative Signal in Early Infection
-
批准号:8076162
-
项目类别:
-
资助金额:$23.17万
-
财政年份:2010
-
负责人:YANG-XIN FU
-
依托单位:
Synergy of Radiation and Immunotherapy: New Approaches
-
批准号:8815505
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2010
-
负责人:YANG-XIN FU
-
依托单位:
海外基金